CDP-choline: 6-month study on toxicity in dogs.

Area of Science:

• Pharmacology and Toxicology
• Animal Health Studies

Background:

• Cytidine diphosphate choline (CDP-choline), also known as citicoline, is a nootropic agent.
• Investigating the safety profile of CDP-choline is crucial for its therapeutic applications.

Purpose of the Study:

• To evaluate the potential toxic effects of a single oral dose of CDP-choline in Beagle dogs.
• To assess the safety of long-term (6-month) CDP-choline administration.

Main Methods:

• Oral administration of 1.5 g/kg CDP-choline daily to 6 Beagle dogs for 6 months.
• Post-treatment assessment included urinalysis, blood analysis, and histopathological examination of tissues.
• Comparison with a control group of untreated Beagle dogs.

Main Results:

• All assessed parameters, including urinalysis, blood chemistry, and histopathology, were within normal physiological ranges.
• Minor variations observed were attributed to individual biological variability, not treatment effects.
• No significant adverse effects or organ damage were detected in the CDP-choline treated group.

Conclusions:

• CDP-choline administration at the tested dosage and duration did not induce any discernible toxic effects in Beagle dogs.
• The study supports the safety of CDP-choline under the specified experimental conditions.
• Further research may explore therapeutic efficacy in various conditions.